Cargando…

Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation

Cell differentiation is an orderly process that begins with modifications in gene expression. This process is regulated by the acetylation state of histones. Removal of the acetyl groups of histones by specific enzymes (histone deacetylases, HDAC) usually downregulates expression of genes that can c...

Descripción completa

Detalles Bibliográficos
Autores principales: Alcarraz-Vizán, Gema, Boren, Joan, Lee, Wai-Nang Paul, Cascante, Marta
Formato: Texto
Lenguaje:English
Publicado: Springer US 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862949/
https://www.ncbi.nlm.nih.gov/pubmed/20445757
http://dx.doi.org/10.1007/s11306-009-0192-0
_version_ 1782180737561133056
author Alcarraz-Vizán, Gema
Boren, Joan
Lee, Wai-Nang Paul
Cascante, Marta
author_facet Alcarraz-Vizán, Gema
Boren, Joan
Lee, Wai-Nang Paul
Cascante, Marta
author_sort Alcarraz-Vizán, Gema
collection PubMed
description Cell differentiation is an orderly process that begins with modifications in gene expression. This process is regulated by the acetylation state of histones. Removal of the acetyl groups of histones by specific enzymes (histone deacetylases, HDAC) usually downregulates expression of genes that can cause cells to differentiate, and pharmacological inhibitors of these enzymes have been shown to induce differentiation in several colon cancer cell lines. Butyrate at high (mM) concentration is both a precursor for acetyl-CoA and a known HDAC inhibitor that induces cell differentiation in colon cells. The dual role of butyrate raises the question whether its effects on HT29 cell differentiation are due to butyrate metabolism or to its HDAC inhibitor activity. To distinguish between these two possibilities, we used a tracer-based metabolomics approach to compare the metabolic changes induced by two different types of HDAC inhibitors (butyrate and the non-metabolic agent trichostatin A) and those induced by other acetyl-CoA precursors that do not inhibit HDAC (caprylic and capric acids). [1,2-(13)C(2)]-d-glucose was used as a tracer and its redistribution among metabolic intermediates was measured to estimate the contribution of glycolysis, the pentose phosphate pathway and the Krebs cycle to the metabolic profile of HT29 cells under the different treatments. The results demonstrate that both HDAC inhibitors (trichostatin A and butyrate) induce a common metabolic profile that is associated with histone deacetylase inhibition and differentiation of HT29 cells whereas the metabolic effects of acetyl-CoA precursors are different from those of butyrate. The experimental findings support the concept of crosstalk between metabolic and cell signalling events, and provide an experimental approach for the rational design of new combined therapies that exploit the potential synergism between metabolic adaptation and cell differentiation processes through modification of HDAC activity.
format Text
id pubmed-2862949
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-28629492010-05-04 Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation Alcarraz-Vizán, Gema Boren, Joan Lee, Wai-Nang Paul Cascante, Marta Metabolomics Original Article Cell differentiation is an orderly process that begins with modifications in gene expression. This process is regulated by the acetylation state of histones. Removal of the acetyl groups of histones by specific enzymes (histone deacetylases, HDAC) usually downregulates expression of genes that can cause cells to differentiate, and pharmacological inhibitors of these enzymes have been shown to induce differentiation in several colon cancer cell lines. Butyrate at high (mM) concentration is both a precursor for acetyl-CoA and a known HDAC inhibitor that induces cell differentiation in colon cells. The dual role of butyrate raises the question whether its effects on HT29 cell differentiation are due to butyrate metabolism or to its HDAC inhibitor activity. To distinguish between these two possibilities, we used a tracer-based metabolomics approach to compare the metabolic changes induced by two different types of HDAC inhibitors (butyrate and the non-metabolic agent trichostatin A) and those induced by other acetyl-CoA precursors that do not inhibit HDAC (caprylic and capric acids). [1,2-(13)C(2)]-d-glucose was used as a tracer and its redistribution among metabolic intermediates was measured to estimate the contribution of glycolysis, the pentose phosphate pathway and the Krebs cycle to the metabolic profile of HT29 cells under the different treatments. The results demonstrate that both HDAC inhibitors (trichostatin A and butyrate) induce a common metabolic profile that is associated with histone deacetylase inhibition and differentiation of HT29 cells whereas the metabolic effects of acetyl-CoA precursors are different from those of butyrate. The experimental findings support the concept of crosstalk between metabolic and cell signalling events, and provide an experimental approach for the rational design of new combined therapies that exploit the potential synergism between metabolic adaptation and cell differentiation processes through modification of HDAC activity. Springer US 2010-01-08 2010 /pmc/articles/PMC2862949/ /pubmed/20445757 http://dx.doi.org/10.1007/s11306-009-0192-0 Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Original Article
Alcarraz-Vizán, Gema
Boren, Joan
Lee, Wai-Nang Paul
Cascante, Marta
Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title_full Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title_fullStr Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title_full_unstemmed Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title_short Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation
title_sort histone deacetylase inhibition results in a common metabolic profile associated with ht29 differentiation
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2862949/
https://www.ncbi.nlm.nih.gov/pubmed/20445757
http://dx.doi.org/10.1007/s11306-009-0192-0
work_keys_str_mv AT alcarrazvizangema histonedeacetylaseinhibitionresultsinacommonmetabolicprofileassociatedwithht29differentiation
AT borenjoan histonedeacetylaseinhibitionresultsinacommonmetabolicprofileassociatedwithht29differentiation
AT leewainangpaul histonedeacetylaseinhibitionresultsinacommonmetabolicprofileassociatedwithht29differentiation
AT cascantemarta histonedeacetylaseinhibitionresultsinacommonmetabolicprofileassociatedwithht29differentiation